JanOne Inc. (JAN): Price and Financial Metrics
GET POWR RATINGS... FREE!
JAN POWR Grades
- JAN scores best on the Momentum dimension, with a Momentum rank ahead of 83.21% of US stocks.
- JAN's strongest trending metric is Sentiment; it's been moving up over the last 64 days.
- JAN's current lowest rank is in the Stability metric (where it is better than 9.31% of US stocks).
JAN Stock Summary
- JAN has a market capitalization of $11,592,381 -- more than approximately only 1.13% of US stocks.
- JanOne Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 97.97% of US listed stocks.
- With a price/sales ratio of 0.3, JanOne Inc has a higher such ratio than merely 5.16% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to JanOne Inc are OMI, BBBY, SGRP, CAL, and GPI.
- Visit JAN's SEC page to see the company's official filings. To visit the company's web site, go to www.janone.com.
JAN Valuation Summary
- JAN's EV/EBIT ratio is -2.5; this is 111.44% lower than that of the median Industrials stock.
- JAN's EV/EBIT ratio has moved down 8.5 over the prior 243 months.
- JAN's EV/EBIT ratio has moved down 8.5 over the prior 243 months.
Below are key valuation metrics over time for JAN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| JAN | 2021-09-03 | 0.4 | 4.6 | -2.0 | -2.5 |
| JAN | 2021-09-02 | 0.4 | 4.4 | -1.9 | -2.4 |
| JAN | 2021-09-01 | 0.4 | 4.6 | -2.0 | -2.5 |
| JAN | 2021-08-31 | 0.4 | 4.4 | -1.9 | -2.4 |
| JAN | 2021-08-30 | 0.4 | 4.6 | -2.0 | -2.5 |
| JAN | 2021-08-27 | 0.4 | 4.6 | -2.0 | -2.5 |
JAN Growth Metrics
- The 5 year net income to common stockholders growth rate now stands at -732.36%.
- The year over year revenue growth rate now stands at -8.5%.
- The 5 year revenue growth rate now stands at -66.02%.
The table below shows JAN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 38.535 | -3.06 | -8.408 |
| 2021-06-30 | 38.688 | -1.302 | -8.25 |
| 2021-03-31 | 34.089 | -1.655 | -5.713 |
| 2020-12-31 | 33.867 | -0.617 | -8.498 |
| 2020-09-30 | 36.136 | -0.909 | -12.142 |
| 2020-06-30 | 33.66 | -4.011 | -13.29 |
JAN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- JAN has a Quality Grade of D, ranking ahead of 11.81% of graded US stocks.
- JAN's asset turnover comes in at 1.474 -- ranking 81st of 165 Retail stocks.
- QRTEA, CNXN, and CVS are the stocks whose asset turnover ratios are most correlated with JAN.
The table below shows JAN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-07-03 | 1.474 | 0.245 | 2.457 |
| 2021-04-03 | 1.317 | 0.257 | 1.776 |
| 2021-01-02 | 1.319 | 0.261 | 3.280 |
| 2020-09-26 | 1.346 | 0.234 | 5.914 |
| 2020-06-27 | 1.169 | 0.217 | -23.137 |
| 2020-03-28 | 1.215 | 0.218 | -6.494 |
JAN Stock Price Chart Interactive Chart >
JAN Price/Volume Stats
| Current price | $2.57 | 52-week high | $8.41 |
| Prev. close | $2.65 | 52-week low | $1.89 |
| Day low | $2.55 | Volume | 110,831 |
| Day high | $2.75 | Avg. volume | 1,282,143 |
| 50-day MA | $2.65 | Dividend yield | N/A |
| 200-day MA | $4.01 | Market Cap | 7.27M |
JanOne Inc. (JAN) Company Bio
JanOne Inc. develops treatments for conditions that cause severe pain. The company, through its non-addictive pain-relieving drugs, focuses on reduction for need of opioid prescriptions to treat disease associated pain that can lead to opioid abuse. Its lead candidate JAN101 provides slow-release formulation of sodium nitrite therapeutic for treatment of peripheral artery disease (PAD). The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Latest JAN News From Around the Web
Below are the latest news stories about JanOne Inc that investors may wish to consider to help them evaluate JAN as an investment opportunity.
Price Capital Management, Inc. Buys JanOne Inc, Sells iShares U.S. ...Lafayette, LA, based Investment company Price Capital Management, Inc. (Current Portfolio) buys JanOne Inc, sells iShares U.S. |
ATP Life Science Ventures, L.P. Buys JanOne IncInvestment company ATP Life Science Ventures, L.P. (Current Portfolio) buys JanOne Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, ATP Life Science Ventures, L.P.. |
JanOne Inc. Develops Plan for Treating Methamphetamine Use DisorderJanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - previously announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). Although meth use has been decreasing in younger individuals, in people over 26 years old, it has been growing at a CAGR of 13% p.a., with just ov |
ARCA Recycling, a Subsidiary of JanOne Inc., Awarded Recycling Contract in Virginia and North Carolina With Total Estimated Value of $1.6 Million for Work through 2023ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), was recently awarded a contract to provide appliance recycling services to customers of a major electric utility in Virginia and North Carolina. The program encourages the early retirement of low-efficiency refrigerators and freezers and will run through 2023. ARCA estimates the total value of the contract awarded to be approximately $1.6 million. |
JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use DisorderJanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides |
JAN Price Returns
| 1-mo | N/A |
| 3-mo | -26.36% |
| 6-mo | -37.16% |
| 1-year | -69.33% |
| 3-year | -41.46% |
| 5-year | -34.94% |
| YTD | -37.16% |
| 2021 | -16.36% |
| 2020 | 65.20% |
| 2019 | 34.55% |
| 2018 | -57.69% |
| 2017 | -7.14% |
Loading social stream, please wait...